Pharmaceutical composition comprising chorion extract-derived exosomes as active ingredient for promoting osteogenesis

Abstract

The present invention relates to a pharmaceutical composition comprising exosomes within a chorion extract as an active ingredient for promoting osteogenesis and preventing and treating bone diseases and, more specifically, to excellent osteogenesis promotion efficacy of exosomes within a chorion extract prepared by extracting the placental chorion.

1 . A pharmaceutical composition for promoting osteogenesis comprising chorion membrane extract-derived extracellular vesicles as an active ingredient. 
     
     
         2 . A pharmaceutical composition for preventing or treating bone diseases comprising chorion membrane extract-derived extracellular vesicles as an active ingredient. 
     
     
         3 . The pharmaceutical composition for preventing or treating bone diseases of  claim 2 , wherein the bone diseases are one selected from the group consisting of bone defects, osteoporosis, osteoporotic fracture, diabetic fractures, fracture nonunion, osteogenesis imperfecta, osteomalacia and fractures resulting therefrom, osteogenesis disorders, degenerative bone diseases, or malocclusion. 
     
     
         4 . The pharmaceutical composition of  claim 1 , wherein the extracellular vesicles are at least one selected from the group consisting of exosomes, microvesicles, or microparticles. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein the extracellular vesicles have a concentration of 1×10 10  to 1×10 12  particles/well. 
     
     
         6 . The pharmaceutical composition of  claim 1 , wherein the extracellular vesicles have an average particle size of 100 nm to 150 nm. 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein the composition is mixed and used with a hydroxyapatite/β-tricalcium phosphate (HA/bTCP) scaffold. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein the composition is formulated into powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injectable solutions. 
     
     
         9 . The pharmaceutical composition of  claim 2 , wherein the extracellular vesicles are at least one selected from the group consisting of exosomes, microvesicles, or microparticles. 
     
     
         10 . The pharmaceutical composition of  claim 2 , wherein the extracellular vesicles have a concentration of 1×10 10  to 1×10 12  particles/well. 
     
     
         11 . The pharmaceutical composition of  claim 2 , wherein the extracellular vesicles have an average particle size of 100 nm to 150 nm. 
     
     
         12 . The pharmaceutical composition of  claim 2 , wherein the composition is mixed and used with a hydroxyapatite/β-tricalcium phosphate (HA/bTCP) scaffold. 
     
     
         13 . The pharmaceutical composition of  claim 2 , wherein the composition is formulated into powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injectable solutions. 
     
     
         14 . The pharmaceutical composition of  claim 3 , wherein the extracellular vesicles are at least one selected from the group consisting of exosomes, microvesicles, or microparticles. 
     
     
         15 . The pharmaceutical composition of  claim 3 , wherein the extracellular vesicles have a concentration of 1×10 10  to 1×10 12  particles/well. 
     
     
         16 . The pharmaceutical composition of  claim 3 , wherein the extracellular vesicles have an average particle size of 100 nm to 150 nm. 
     
     
         17 . The pharmaceutical composition of  claim 3 , wherein the composition is mixed and used with a hydroxyapatite/β-tricalcium phosphate (HA/bTCP) scaffold. 
     
     
         18 . The pharmaceutical composition of  claim 3 , wherein the composition is formulated into powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, or sterile injectable solutions.